-
1
-
-
84952995689
-
-
Howlader N, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2014) SEER Cancer Statistics Review, 1975–2011. National Cancer Institute, Bethesda
-
Howlader N, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2014) SEER Cancer Statistics Review, 1975–2011. National Cancer Institute, Bethesda
-
-
-
-
2
-
-
0034085989
-
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
-
COI: 1:STN:280:DC%2BD3c3psVartA%3D%3D, PID: 10836297
-
Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583
-
(2000)
Hum Pathol
, vol.31
, pp. 578-583
-
-
Bubendorf, L.1
Schopfer, A.2
Wagner, U.3
Sauter, G.4
Moch, H.5
Willi, N.6
Gasser, T.C.7
Mihatsch, M.J.8
-
3
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
COI: 1:CAS:528:DC%2BD2cXot1Kmu7s%3D, PID: 15470213
-
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi:10.1056/NEJMoa040720
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
4
-
-
34548584066
-
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
-
PID: 17262196
-
DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876. doi:10.1007/s00520-006-0203-x
-
(2007)
Support Care Cancer
, vol.15
, pp. 869-876
-
-
DePuy, V.1
Anstrom, K.J.2
Castel, L.D.3
Schulman, K.A.4
Weinfurt, K.P.5
Saad, F.6
-
5
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
-
PID: 20888992
-
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators T (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154. doi:10.1016/S0140-6736(10)61389-X
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
de Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
Hansen, S.4
Machiels, J.P.5
Kocak, I.6
Gravis, G.7
Bodrogi, I.8
Mackenzie, M.J.9
Shen, L.10
Roessner, M.11
Gupta, S.12
Sartor, A.O.13
Investigators, T.14
-
6
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
COI: 1:CAS:528:DC%2BC3cXhtVGlurrN, PID: 20818862
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
Redfern, C.H.7
Ferrari, A.C.8
Dreicer, R.9
Sims, R.B.10
Xu, Y.11
Frohlich, M.W.12
Schellhammer, P.F.13
-
7
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
PID: 21612468
-
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C-A (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005. doi:10.1056/NEJMoa1014618
-
(2011)
N Engl J Med
, vol.364
, pp. 1995-2005
-
-
de Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
Fizazi, K.4
North, S.5
Chu, L.6
Chi, K.N.7
Jones, R.J.8
Goodman, O.B.9
Saad, F.10
Staffurth, J.N.11
Mainwaring, P.12
Harland, S.13
Flaig, T.W.14
Hutson, T.E.15
Cheng, T.16
Patterson, H.17
Hainsworth, J.D.18
Ryan, C.J.19
Sternberg, C.N.20
Ellard, S.L.21
Fléchon, A.22
Saleh, M.23
Scholz, M.24
Efstathiou, E.25
Zivi, A.26
Bianchini, D.27
Loriot, Y.28
Chieffo, N.29
Kheoh, T.30
Haqq, C.M.31
Scher, H.I.32
Investigators C-A33
more..
-
8
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
COI: 1:CAS:528:DC%2BC3sXovVyhtw%3D%3D, PID: 23228172
-
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, Investigators C-A (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148. doi:10.1056/NEJMoa1209096
-
(2013)
N Engl J Med
, vol.368
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
de Bono, J.S.3
Molina, A.4
Logothetis, C.J.5
de Souza, P.6
Fizazi, K.7
Mainwaring, P.8
Piulats, J.M.9
Ng, S.10
Carles, J.11
Mulders, P.F.12
Basch, E.13
Small, E.J.14
Saad, F.15
Schrijvers, D.16
Van Poppel, H.17
Mukherjee, S.D.18
Suttmann, H.19
Gerritsen, W.R.20
Flaig, T.W.21
George, D.J.22
Yu, E.Y.23
Efstathiou, E.24
Pantuck, A.25
Winquist, E.26
Higano, C.S.27
Taplin, M.E.28
Park, Y.29
Kheoh, T.30
Griffin, T.31
Scher, H.I.32
Rathkopf, D.E.33
Investigators C-A34
more..
-
9
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
COI: 1:CAS:528:DC%2BC38XhsVKhsLvK, PID: 22894553
-
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Investigators A (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. doi:10.1056/NEJMoa1207506
-
(2012)
N Engl J Med
, vol.367
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
Taplin, M.E.4
Sternberg, C.N.5
Miller, K.6
de Wit, R.7
Mulders, P.8
Chi, K.N.9
Shore, N.D.10
Armstrong, A.J.11
Flaig, T.W.12
Fléchon, A.13
Mainwaring, P.14
Fleming, M.15
Hainsworth, J.D.16
Hirmand, M.17
Selby, B.18
Seely, L.19
de Bono, J.S.20
Investigators, A.21
more..
-
10
-
-
84908450155
-
Enzalutamide in metastatic prostate cancer before chemotherapy
-
PID: 24881730
-
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433. doi:10.1056/NEJMoa1405095
-
(2014)
N Engl J Med
, vol.371
, pp. 424-433
-
-
Beer, T.M.1
Armstrong, A.J.2
Rathkopf, D.E.3
Loriot, Y.4
Sternberg, C.N.5
Higano, C.S.6
Iversen, P.7
Bhattacharya, S.8
Carles, J.9
Chowdhury, S.10
Davis, I.D.11
de Bono, J.S.12
Evans, C.P.13
Fizazi, K.14
Joshua, A.M.15
Kim, C.S.16
Kimura, G.17
Mainwaring, P.18
Mansbach, H.19
Miller, K.20
Noonberg, S.B.21
Perabo, F.22
Phung, D.23
Saad, F.24
Scher, H.I.25
Taplin, M.E.26
Venner, P.M.27
Tombal, B.28
more..
-
11
-
-
0023751783
-
Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma
-
COI: 1:STN:280:DyaL1M%2FjtVOrug%3D%3D, PID: 2460352
-
Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K (1988) Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14:349–351
-
(1988)
Eur J Nucl Med
, vol.14
, pp. 349-351
-
-
Buchali, K.1
Correns, H.J.2
Schuerer, M.3
Schnorr, D.4
Lips, H.5
Sydow, K.6
-
12
-
-
33746883985
-
Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease
-
PID: 16985930
-
Sartor O (2004) Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol 6(Suppl 10):S3–S12
-
(2004)
Rev Urol
, vol.6
, pp. S3-S12
-
-
Sartor, O.1
-
13
-
-
33746707858
-
223Ra: adjuvant or alternative to conventional modalities?
-
COI: 1:CAS:528:DC%2BD28XhtFWhsbfK, PID: 17062709
-
223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12:6250s–6257s. doi:10.1158/1078-0432.ccr-06-0841
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6250s-6257s
-
-
Bruland, O.S.1
Nilsson, S.2
Fisher, D.R.3
Larsen, R.H.4
-
15
-
-
84860677986
-
223Ra alpha-emitter radiopharmaceutical therapy
-
COI: 1:CAS:528:DC%2BC38XhtVGgs7%2FN, PID: 22546715
-
223Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol 57:3207–3222. doi:10.1088/0031-9155/57/10/3207
-
(2012)
Phys Med Biol
, vol.57
, pp. 3207-3222
-
-
Hobbs, R.F.1
Song, H.2
Watchman, C.J.3
Bolch, W.E.4
Aksnes, A.K.5
Ramdahl, T.6
Flux, G.D.7
Sgouros, G.8
-
16
-
-
0036606104
-
Significant antitumor effect from bone-seeking, alpha-particle-emitting (223) Ra demonstrated in an experimental skeletal metastases model
-
COI: 1:CAS:528:DC%2BD38XksVyqsrY%3D, PID: 12036923
-
Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH (2002) Significant antitumor effect from bone-seeking, alpha-particle-emitting (223) Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62:3120–3125
-
(2002)
Cancer Res
, vol.62
, pp. 3120-3125
-
-
Henriksen, G.1
Breistol, K.2
Bruland, O.S.3
Fodstad, O.4
Larsen, R.H.5
-
17
-
-
84882992707
-
Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis
-
PID: 23682134
-
Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Kakonen SM, Scholz A (2013) Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst 105:908–916. doi:10.1093/jnci/djt116
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 908-916
-
-
Suominen, M.I.1
Rissanen, J.P.2
Kakonen, R.3
Fagerlund, K.M.4
Alhoniemi, E.5
Mumberg, D.6
Ziegelbauer, K.7
Halleen, J.M.8
Kakonen, S.M.9
Scholz, A.10
-
18
-
-
20644447798
-
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
-
COI: 1:CAS:528:DC%2BD2MXltFeksrc%3D, PID: 15958630
-
Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11:4451–4459. doi:10.1158/1078-0432.ccr-04-2244
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4451-4459
-
-
Nilsson, S.1
Larsen, R.H.2
Fossa, S.D.3
Balteskard, L.4
Borch, K.W.5
Westlin, J.E.6
Salberg, G.7
Bruland, O.S.8
-
19
-
-
84881630281
-
223Ra-dichloride in men with castration-resistant metastatic prostate cancer
-
COI: 1:CAS:528:DC%2BC3sXht1Gmu7fF, PID: 23653243
-
223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 40:1384–1393. doi:10.1007/s00259-013-2427-6
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, pp. 1384-1393
-
-
Carrasquillo, J.A.1
O’Donoghue, J.A.2
Pandit-Taskar, N.3
Humm, J.L.4
Rathkopf, D.E.5
Slovin, S.F.6
Williamson, M.J.7
Lacuna, K.8
Aksnes, A.K.9
Larson, S.M.10
Scher, H.I.11
Morris, M.J.12
-
20
-
-
34347244905
-
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
-
COI: 1:CAS:528:DC%2BD2sXnsFKkurw%3D, PID: 17544845
-
Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8:587–594. doi:10.1016/s1470-2045(07)70147-x
-
(2007)
Lancet Oncol
, vol.8
, pp. 587-594
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
Tyrrell, C.4
Blom, R.5
Tennvall, J.6
Lennernas, B.7
Petersson, U.8
Johannessen, D.C.9
Sokal, M.10
Pigott, K.11
Yachnin, J.12
Garkavij, M.13
Strang, P.14
Harmenberg, J.15
Bolstad, B.16
Bruland, O.S.17
-
21
-
-
84858706749
-
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
-
COI: 1:CAS:528:DC%2BC38Xkt1Gmt78%3D, PID: 22341993
-
Nilsson S, Strang P, Aksnes AK, Franzen L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland OS (2012) A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 48:678–686. doi:10.1016/j.ejca.2011.12.023
-
(2012)
Eur J Cancer
, vol.48
, pp. 678-686
-
-
Nilsson, S.1
Strang, P.2
Aksnes, A.K.3
Franzen, L.4
Olivier, P.5
Pecking, A.6
Staffurth, J.7
Vasanthan, S.8
Andersson, C.9
Bruland, O.S.10
-
22
-
-
84871926771
-
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer
-
COI: 1:CAS:528:DC%2BC38XhsVSltLvP, PID: 23000088
-
Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germa JR, O’Bryan-Tear CG, Haider T, Hoskin P (2013) A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63:189–197. doi:10.1016/j.eururo.2012.09.008
-
(2013)
Eur Urol
, vol.63
, pp. 189-197
-
-
Parker, C.C.1
Pascoe, S.2
Chodacki, A.3
O’Sullivan, J.M.4
Germa, J.R.5
O’Bryan-Tear, C.G.6
Haider, T.7
Hoskin, P.8
-
23
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
COI: 1:CAS:528:DC%2BC3sXhtFKls77M, PID: 23863050
-
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzen L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. doi:10.1056/NEJMoa1213755
-
(2013)
N Engl J Med
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
Helle, S.I.4
O’Sullivan, J.M.5
Fossa, S.D.6
Chodacki, A.7
Wiechno, P.8
Logue, J.9
Seke, M.10
Widmark, A.11
Johannessen, D.C.12
Hoskin, P.13
Bottomley, D.14
James, N.D.15
Solberg, A.16
Syndikus, I.17
Kliment, J.18
Wedel, S.19
Boehmer, S.20
Dall’Oglio, M.21
Franzen, L.22
Coleman, R.23
Vogelzang, N.J.24
O’Bryan-Tear, C.G.25
Staudacher, K.26
Garcia-Vargas, J.27
Shan, M.28
Bruland, O.S.29
Sartor, O.30
more..
-
24
-
-
84901638475
-
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
-
COI: 1:CAS:528:DC%2BC2cXotFyrs74%3D, PID: 24836273
-
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland OS, Parker C (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15:738–746. doi:10.1016/s1470-2045(14)70183-4
-
(2014)
Lancet Oncol
, vol.15
, pp. 738-746
-
-
Sartor, O.1
Coleman, R.2
Nilsson, S.3
Heinrich, D.4
Helle, S.I.5
O’Sullivan, J.M.6
Fossa, S.D.7
Chodacki, A.8
Wiechno, P.9
Logue, J.10
Widmark, A.11
Johannessen, D.C.12
Hoskin, P.13
James, N.D.14
Solberg, A.15
Syndikus, I.16
Vogelzang, N.J.17
O’Bryan-Tear, C.G.18
Shan, M.19
Bruland, O.S.20
Parker, C.21
more..
-
25
-
-
84908594586
-
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
-
COI: 1:CAS:528:DC%2BC2cXhsl2hu7fE, PID: 25439694
-
Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15:1397–1406. doi:10.1016/s1470-2045(14)70474-7
-
(2014)
Lancet Oncol
, vol.15
, pp. 1397-1406
-
-
Hoskin, P.1
Sartor, O.2
O’Sullivan, J.M.3
Johannessen, D.C.4
Helle, S.I.5
Logue, J.6
Bottomley, D.7
Nilsson, S.8
Vogelzang, N.J.9
Fang, F.10
Wahba, M.11
Aksnes, A.K.12
Parker, C.13
-
26
-
-
84952994784
-
-
ASCO, Genitourinary cancers symposium:
-
Nilsson S, Sartor O, Bottomley D, Coleman R, Skjorestad I, Wahba M, Parker C (2014) 1.5-Year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA Study 9. ASCO 2014 Genitourinary cancers symposium
-
(2014)
Parker C (2014) 1.5-Year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA Study
, vol.9
-
-
Nilsson, S.1
Sartor, O.2
Bottomley, D.3
Coleman, R.4
Skjorestad, I.5
Wahba, M.6
-
27
-
-
70349785587
-
Incidence of leukaemia and other malignant diseases following injections of the short-lived alpha-emitter 224Ra into man
-
PID: 19475414
-
Wick RR, Atkinson MJ, Nekolla EA (2009) Incidence of leukaemia and other malignant diseases following injections of the short-lived alpha-emitter 224Ra into man. Radiat Environ Biophys 48:287–294. doi:10.1007/s00411-009-0227-y
-
(2009)
Radiat Environ Biophys
, vol.48
, pp. 287-294
-
-
Wick, R.R.1
Atkinson, M.J.2
Nekolla, E.A.3
-
28
-
-
0032733453
-
Malignancies in patients treated with high doses of radium-224
-
COI: 1:CAS:528:DyaK1MXnvFynsrw%3D, PID: 10564925
-
Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H (1999) Malignancies in patients treated with high doses of radium-224. Radiat Res 152:S3–S7
-
(1999)
Radiat Res
, vol.152
, pp. S3-S7
-
-
Nekolla, E.A.1
Kellerer, A.M.2
Kuse-Isingschulte, M.3
Eder, E.4
Spiess, H.5
-
29
-
-
84952993221
-
Effects of radium-223 dichloride (Ra-223) on risk for hospitalization and health care resource use in the phase 3 ALSYMPCA trial
-
Cislo P, Reuning-Scherer J (2014) Effects of radium-223 dichloride (Ra-223) on risk for hospitalization and health care resource use in the phase 3 ALSYMPCA trial. ASCO quality care symposium
-
(2014)
ASCO quality care symposium
-
-
Cislo, P.1
Reuning-Scherer, J.2
|